# Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

> **NCT05359146** · EARLY_PHASE1 · UNKNOWN · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 16 (estimated)

## Conditions studied

- Neuroendocrine Neoplasia's (NENs)
- Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

## Interventions

- **DRUG:** 161Tb-DOTA-LM3
- **DRUG:** 177Lu-DOTATOC

## Key facts

- **NCT ID:** NCT05359146
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-28
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359146, "Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05359146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*